Educational content, not medical advice. This article reports a drug interaction warning exactly as the GLP-1 labels state it. The dose of any medicine, including a companion one, belongs with the prescriber who manages the whole regimen.

Among companion medicines, one class gets named in every single GLP-1 label, and it is the one with no page of its own. Metformin has Metformin Plus a GLP-1: The Most Common Pairing, the SGLT2 inhibitors have GLP-1s and SGLT2 Inhibitors: Two Different Jobs, and the DPP-4 inhibitors have DPP-4 Inhibitors: The Other Way to Raise GLP-1. The sulfonylureas, and insulin, appear in passing across this site and across the class, always in the same breath: a warning about low blood sugar. That warning deserves a full reading, because its wording is more precise, and more one-directional, than a phrase like “drug interaction” suggests.

The combination itself is unremarkable in practice. People frequently arrive at a GLP-1 already taking other glucose-lowering medicines, and the labels assume that reality rather than forbidding it; the warning section exists to manage it, not to rule it out. Whether any individual's combination is appropriate is a question only their prescriber can answer, and nothing in this article substitutes for that.

The warning, nearly word for word across the class

Under a heading usually rendered as Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin, the labels state that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia, and that reducing the dose of the insulin secretagogue or insulin may be necessary. That is the wording on Ozempic, Wegovy, the shared Rybelsus and Ozempic tablets label, Zepbound, Mounjaro, Saxenda, Victoza, Trulicity and Byetta, checked on each label on November 2, 2026. A warning that reads nearly the same across molecules and sponsors is itself worth noticing. Whatever differences separate these medicines, this caution is not one of them.

The labels say “an insulin secretagogue (e.g., sulfonylurea)”, and no individual sulfonylurea is named anywhere in them. The mechanism explains the caution. A secretagogue is a drug that makes the pancreas release insulin regardless of what blood sugar is doing at that moment, so the insulin arrives on the drug's schedule rather than in response to a meal. Combine that with a medicine that also lowers glucose, and the two effects stack: the warning exists because the stack can push glucose below where the body is comfortable. That is the entire explanation the labels offer, and it is enough to make sense of the rest.

The direction of the dose change

Read the warning a second time and notice where the reduction points. Every one of those labels, without exception, describes reducing the dose of the companion medicine, the insulin or the insulin secretagogue. Not one describes reducing the GLP-1 for this reason. That asymmetry is the whole structure of the interaction as the labels see it: the GLP-1 is the incoming medicine, and the secretagogue or insulin is the one whose dose may need to move to accommodate it.

Note how much the labels leave open. They say a reduction may be necessary; they do not say by how much, for whom, or when, and they leave every one of those decisions to the prescriber managing the regimen. A reader's own insulin or sulfonylurea dose was set for a reason and can only be re-set with the full picture in view. Every mention of dose change in this article points back to the same sentence: it is the prescriber's call, every time, for every medicine involved.

GLP 1 Tracker AppDated dose entries for every medication it supports, with notes, so the whole regimen sits on one timeline your prescriber can actually read. Free, no account, nothing leaves your phone. Get the app

The one trial that puts numbers on it

Every label states the warning in words; one label also quantifies it. In a trial of patients with type 2 diabetes and a BMI of 27 or above, hypoglycemia defined as plasma glucose below 54 mg/dL was reported in 4.2 percent of Zepbound patients against 1.3 percent on placebo. Within that same trial, patients taking Zepbound with an insulin secretagogue recorded a rate of 10.3 percent, against 2.1 percent for Zepbound patients not taking a sulfonylurea. Those figures are what the other labels state in prose: the combination raises the rate of lows substantially, in the population that was studied. They are trial results, not a prediction about any reader, and they describe Zepbound specifically rather than the class.

Three labels with their own angle

Within the shared wording, a few labels add something of their own. Saxenda phrases the risk as hypoglycemia that can occur when Saxenda is used with an insulin secretagogue or insulin, with the risk possibly lowered by a reduction in the dose of the concomitant drug, the same direction of change in softer verbs. Victoza adds a pediatric observation: in patients aged 10 years and older, the risk of hypoglycemia was higher with Victoza regardless of insulin or metformin use, which widens the caution beyond the combination. Byetta is the only one that shows the combination in its adverse reaction tables rather than only in words: added to a sulfonylurea, vomiting was 13 percent against 4 percent on placebo, and added to insulin glargine, 18 percent against 4 percent. What the short-acting agents are and how they differ is covered at Byetta and the Short-Acting GLP-1s.

Metformin, the contrast that makes the point

Metformin is worth one paragraph precisely because it is not an insulin secretagogue. It does not carry this warning in the same way, which is why its pairing page reads so differently from this one. That difference is about mechanism, not a ranking of the two medicines, and it is the clearest illustration that the sulfonylurea warning is a specific claim about a specific way of lowering glucose, not a general caution about combining anything with a GLP-1.

What a low looks like, and what to bring

The symptoms of low blood sugar, and the situations on a GLP-1 in which lows become possible at all, belong to GLP-1s and Blood Sugar: When Lows Become Possible, which carries them in full. The practical counterpart is the appointment. A prescriber weighing this warning for a specific person wants dates: which medicines on which days, and what happened around them. GLP 1 Tracker keeps dated dose entries for every medication it supports, and a free-text note attaches to a dose entry, so the GLP-1 and the companion medicine sit on one timeline rather than in two separate memories. The visit itself, and what to bring to it, is laid out in Make Your Next Appointment Count: Bringing Data to the Doctor.

Frequently asked questions

Why does my GLP-1 label warn about sulfonylureas and insulin?

Because the effects stack. Every GLP-1 label states, under the heading Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin, that using the medicine together with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia, and that reducing the dose of the insulin secretagogue or insulin may be necessary. A secretagogue pushes the pancreas to release insulin regardless of what blood sugar is doing, which is why the labels single the class out.

What is an insulin secretagogue?

A drug that makes the pancreas release insulin regardless of what blood sugar is doing at that moment. Sulfonylureas are the example the GLP-1 labels use, written as an insulin secretagogue, with sulfonylurea given as the example; no individual sulfonylurea is named anywhere in these labels. Combined with a medicine that also lowers glucose, the two effects can add up, which is the reason for the warning.

Will my insulin or sulfonylurea dose need to change when I start a GLP-1?

Sometimes, and the labels say so: they state that reducing the dose of the insulin secretagogue or insulin may be necessary. The decision is made by the prescriber, with the full regimen and glucose record in front of them, and it can change over time. It is never a decision to make alone, because a dose set for one medicine can become too much once another is added.

Does metformin carry the same warning as sulfonylureas?

No. Metformin is not an insulin secretagogue, and the hypoglycemia warning that names insulin secretagogues and insulin does not attach to it in the same way. That difference is about how the two medicines work, not a ranking of them, and metformin plus a GLP-1 remains the most common pairing in practice. Reading the two companion pages side by side shows how differently the labels treat them.

What should I show my prescriber at an appointment about this combination?

A dated record of every medicine taken, with what happened on which days. GLP 1 Tracker keeps dated dose entries for every medication it supports, and a free-text note can be attached to a dose entry, so the GLP-1, the insulin or sulfonylurea, and any symptoms sit on one timeline a prescriber can read at a glance instead of reconstructing from memory.